About Myricx Bio
Myricx Bio is a Healthcare company based in London (United Kingdom) founded in 2019, and was acquired by Novartis in July 2026. Antibody drug conjugates are developed for cancer treatment. Myricx Bio has raised $120.56 million across 2 funding rounds from investors including Lilly, Novartis and Abingworth. The company has 6 employees. Its chief executive, as recorded, is Robin Carr. Myricx Bio offers products and services including NMTi-ADCs and Pipeline Development. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is MYRICX PHARMA LIMITED.
Company details
Myricx Bio was founded in 2019 and is based in London, United Kingdom. A pipeline of proprietary antibody drug conjugates is being developed, utilizing a novel N-myristoyltransferase inhibitor payload chemistry platform. Operations center on oncology, with efforts directed toward addressing unmet medical needs through targeted therapies for cancer.
- Headquarters London, United Kingdom
- Employees 6
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website myricxbio.com
- Social LinkedIn
- Acquired by Novartis (Jul 2026)
- Legal Name Myricx Pharma Limited
- Date of Incorporation 03 Jul, 2019
- Jurisdiction LONDON, UNITED KINGDOM
Products & Services of Myricx Bio
Myricx Bio offers a comprehensive portfolio of products and services, including NMTi-ADCs and Pipeline Development.
ADCs inhibiting NMT for cancer treatment in preclinical stages
Advancing oncology solutions with efficacy across tumor types
Funding Insights of Myricx Bio
Myricx Bio has successfully raised a total of $120.56M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $114 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $120.56M
- Total Rounds 2
- Last Round Series A — $114M
- First Round $6.56M
(Oct 2019)
- Investors Count 7
All 2 funding rounds of Myricx Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2024 | $114M | Series A | – | British Patient Capital, Novo Holdings | |
| Oct 2019 | $6.56M | Seed | – | Sofinnova Partners, Brandon Capital | – |
8 investors in total: 8 institutional.
Investors in Myricx Bio
Myricx Bio has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Novartis and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital co-investments are made in UK later-stage businesses. | britishpatientcapital.co.uk | Sheffield, United Kingdom | ||
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Early-stage medical companies are funded by this venture capital firm. | brandoncapital.vc | Melbourne, Australia | ||
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
Supports cancer research innovation, funding, partnerships, and licensing for treatments. | 1902 | cancerresearchhorizons.com | London, United Kingdom | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States | |
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland |
Investor details for Myricx Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Myricx Bio
1 people are tracked at Myricx Bio (1 in leadership); the tracked headcount is 6.
| Name | Role | Group |
|---|---|---|
Robin Carr | CEO | Leadership |
Complete people profiles for Myricx Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Myricx Bio
4 dated milestones of Myricx Bio across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Myricx Bio is founded.
- Funding First funding round of $6.6M.
- Funding Latest funding round, Series A, of $114.0M.
- Exit Acquired by Novartis.
Web traffic of Myricx Bio
The website of Myricx Bio (myricxbio.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▼ 21.2% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Myricx Bio
Complete news archive for Myricx Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Myricx Bio
Myricx Bio was founded in 2019.
Myricx Bio is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Robin Carr is the CEO of Myricx Bio, as recorded in our data.
Myricx Bio is a funded company, having raised a total of $120.56M across 2 funding rounds to date. The company's 1st funding round was a Seed of $6.56M, raised on Oct 2019.
Myricx Bio has 6 employees.
Myricx Bio was founded in 2019 and is based in London, United Kingdom. A pipeline of proprietary antibody drug conjugates is being developed, utilizing a novel N-myristoyltransferase inhibitor payload chemistry platform. Operations center on oncology, with efforts directed toward addressing unmet medical needs through targeted therapies for cancer.
Myricx Bio offers NMTi-ADCs and Pipeline Development.
Myricx Bio has 8 investors. Key investors include Lilly, Novartis, Abingworth, British Patient Capital, and Novo Holdings.
Myricx Bio operates through Myricx Pharma Limited.
Yes. Myricx Bio was acquired by Novartis in July 2026.